Last updated: November 16, 2026. This page is updated monthly, newest first. Each item below is dated and sourced; older items are kept under "Earlier in 2026" so the page does not decay into a stale-content signal.
November 2026
1. EVOKE and EVOKE+ Alzheimer's Trials: Negative Results
Novo Nordisk's EVOKE and EVOKE+ phase 3 trials tested oral semaglutide in early Alzheimer's disease — 3,808 participants over 104 weeks. The trials were completed in 2026 and the results were negative: no difference from placebo on the CDR-SB cognitive scale. The findings were published in The Lancet in 2026, and the extension study was discontinued.
What this means: the idea that a GLP-1 could slow Alzheimer's had real trial data behind it, and the trials answered the question — for oral semaglutide in early Alzheimer's, the answer was no. It does not change semaglutide's approved uses for diabetes and weight management. See our GLP-1 and brain health guide for the full trial-status table.
2. Foundayo Earns a Positive CHMP Opinion in Europe (October 15, 2026)
The European Medicines Agency's CHMP issued a positive opinion for Foundayo (orforglipron) on October 15, 2026 — the step before a European marketing authorization. Foundayo is a different drug from semaglutide (an oral small-molecule GLP-1, not a peptide), and its main edge over the Wegovy pill is that it has no food or water restrictions. Read our Foundayo EMA opinion article.
3. CagriSema: Still Awaiting an FDA Decision
As of November 2026, CagriSema (semaglutide + cagrilintide) remains under FDA review, with a decision expected in late 2026 or early 2027. Nothing has changed since the May update below — no approval, no rejection, no new date. If approved, launch would likely follow in 2027.
Earlier in 2026
The semaglutide landscape shifted significantly in May 2026. Ozempic oral tablets are now at pharmacies, Wegovy HD is available, and the pipeline behind them keeps growing. Here's what happened.
Ozempic Oral Tablets Now at US Pharmacies (May 4)
Ozempic oral tablets launched at US pharmacies on May 4, 2026. This is a milestone: the first oral peptide GLP-1 receptor agonist with demonstrated MACE (Major Adverse Cardiovascular Events) reduction.
Available doses:
- 1.5 mg — Starting dose
- 4 mg — Maintenance dose
- 9 mg — Higher maintenance dose
Like Rybelsus, the tablets require taking on an empty stomach with no more than 4 oz of water, then waiting 30 minutes before eating or drinking. If you want an oral GLP-1 without food restrictions, Foundayo is an alternative — but it uses a different drug (orforglipron), not semaglutide.
For the full breakdown of oral GLP-1 options, see our GLP-1 Pill Guide and Wegovy Pill vs Injection.
Wegovy HD (7.2 mg) — Approved March 2026
The FDA approved Wegovy HD (semaglutide 7.2 mg) on March 19, 2026, after a 54-day fast-track review. It's triple the standard 2.4 mg maintenance dose.
Key data:
- 20.7% average weight loss at 72 weeks in clinical trials
- Not a starting dose — for patients already on 2.4 mg Wegovy for at least 4 weeks
- Now available at pharmacies as of April 2026
Wegovy HD is for people who plateaued on the standard dose and need more. See our full Wegovy HD Guide for eligibility, dosing, and side effects.
Wegovy Pill (Oral Semaglutide 25 mg) — Approved December 2025
Separate from the Ozempic tablet above, the Wegovy pill (oral semaglutide 25 mg) is a distinct weight-management product that the FDA approved in December 2025 and Novo Nordisk launched at US pharmacies in January 2026. In the OASIS 4 trial, adherent patients lost an average of 16.6% of body weight. A 50 mg dose was studied in the earlier OASIS 1 trial (~15% weight loss) but remains investigational and is not FDA-approved.
This gives patients another needle-free option beyond the 9 mg ceiling of the diabetes-indicated Ozempic tablet. See our Wegovy Pill Doses guide for the full titration schedule.
GLP-1 medication news, in plain English
New approvals, pens, pills, prices and label changes across GLP-1 medications. One free email a week.
CagriSema — FDA Under Review (May 2026 Status)
CagriSema combines semaglutide with cagrilintide (an amylin analog) for dual appetite suppression. Phase 3 REDEFINE 1 trial results showed 20.4% average weight loss over 68 weeks — beating semaglutide alone (13.7%).
Important: CagriSema is not approved. Novo Nordisk submitted its FDA application in late 2025, and a decision is expected in late 2026 or early 2027. If approved, launch would likely follow in 2027.
Read the full breakdown in our CagriSema guide.
Generic Timeline: Still Years Away (May 2026)
Semaglutide does not yet have a generic version in the United States. Key dates:
| Brand | Earliest Expected Generic |
|---|---|
| Ozempic | 2031 |
| Wegovy | 2032 |
Patent litigation could shift these dates, but for now, no generic semaglutide is coming soon. The compounded semaglutide market continues to evolve, but compounded drugs are not FDA-approved and carry quality risks. For ongoing product liability cases, see our Ozempic lawsuits tracker.
See our Semaglutide Generic Availability guide for the full picture.
Novo Nordisk Shortage Status (May 2026)
Supply is improving as of May 2026. Key points:
- Wegovy 2.4 mg is now more widely available
- Ozempic 1 mg and 2 mg still face periodic shortages
- Novo Nordisk and Eli Lilly have expanded manufacturing capacity
- Most doses are expected to be consistently available by late 2026
For current availability and what to do if your medication is out of stock, see our GLP-1 Shortages guide.
Mounjaro Receives a Cardiovascular Indication (August 28, 2026)
The FDA approved Mounjaro (tirzepatide) on August 28, 2026 to lower the risk of cardiovascular death, nonfatal heart attack, and nonfatal stroke in adults with type 2 diabetes who are at high risk for these events.
SURPASS-CVOT found Mounjaro noninferior to Trulicity for MACE-3, but it did not establish superiority. See our Mounjaro cardiovascular approval analysis for what the 8% relative-hazard figure means. For prices across GLP-1s, see our GLP-1 Cost Comparison guide.
The Bottom Line
November 2026: oral semaglutide's Alzheimer's trials came back negative, Foundayo moved a step closer in Europe, and CagriSema is still waiting on the FDA. The May launches — oral Ozempic tablets, Wegovy HD, the Wegovy pill — are all now established options. Generics remain years away. Work with your doctor to find the right option for you, and stay informed through reliable sources.
This article is for information only. Always talk to your doctor for personalized medical advice. For FDA updates, visit fda.gov.
Helpful Products for GLP-1 Treatment
Managing your GLP-1 medication is easier with the right tools:
- Sharps container — Essential for safe needle disposal. A sharps container is required for home use.
- Ginger products — Manage nausea with ginger chews or ginger tea.
- Water bottle — Stay hydrated to reduce side effects. A large water bottle helps you track intake.
- Electrolyte packets — Prevent dehydration. Liquid I.V. packets dissolve easily in water.
GLPSpot may earn from qualifying purchases.








